CIRCULATING CELL-FREE TUMOR DNA MARKET ANALYSIS

Circulating Cell-Free Tumor DNA MarketSize and Trends

The global Circulating Cell-free Tumor DNA Market is estimated to be valued at US$ 6.1 billion in 2023 and is expected to exhibit a CAGR of 22.9% during the forecast period (2023-2030).

Figure 1. Global Circulating Cell-free Tumor DNA Market Share (%), by Application, 2023

Figure 2. Global Circulating Cell-free Tumor DNA Market Value (US$ billion), by Region, 2023

Global Circulating Cell-free Tumor DNA Market Cross Sectional Analysis:

In cancer type segment, lung cancer holds a dominant segment in North America region due to the increasing prevalence of lung cancer. For instance, in November 2022, an article published by Jobson Medical Information LLC, a premier healthcare information and marketing services company, stated that approximately 236,740 new cases of lung cancer were projected in the year 2022.

Global Circulating Cell-free Tumor DNA Market: Key Developments

Increasing research and development activities and product launch by key players in the market is expected to generate new opportunities in the global Circulating Cell-free Tumor DNA Market.

Global Circulating Cell-free Tumor DNA Market - Key Players

Major players operating in the global Circulating Cell-free Tumor DNA Market include Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.

Global Circulating Cell-free Tumor DNA Market– Insights

The term "circulating tumor DNA" (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length.